ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "meta-analysis"

  • Abstract Number: 2614 • ACR Convergence 2024

    Risk of New Onset of Immune-Mediated Diseases After Sars-Cov-2 Infection: A Systematic Review and Meta-Analysis

    Ana Milena Gil1, Julián Barahona-Correa2, Jorge Bruce Flórez-Suárez3, Daniel Fernández-Ávila4 and Zulma Cucunubá1, 1Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogotá, Colombia, 2Division of Rheumatology, Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogotá, Colombia, 3Department of Immunology, Universidad Nacional de Colombia, Bogotá, Colombia, 45Hospital San Ignacio, Colombia, BOGOTA, Colombia

    Background/Purpose: The association between SARS-CoV-2 infection and the new onset of immune-mediated diseases is a topic of interest given the conflicting evidence available. This systematic…
  • Abstract Number: 0726 • ACR Convergence 2024

    Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review

    Emma Neary1, Katie Healey2, Marie Clements-Baker3, Jean-Paul Makhzoum4 and Arielle Mendel5, 1McGill University, Montreal, QC, Canada, 2Memorial University of Newfoundland, St. John's, NL, Canada, 3Queen's University, Kingston, ON, Canada, 4Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, 5McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Ocular manifestations are common in ANCA-associated vasculitides (AAV), with orbital inflammatory disease (OID) representing a significant subset. Despite being a vision-threatening complication, OID remains…
  • Abstract Number: 0787 • ACR Convergence 2024

    Efficacy of Intra-Articular Hyaluronic Acid Injection for Nonsurgical Management of Carpometacarpal Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials

    Mohamed Abdelsalam1, omnia Samy2 and Asmaa al-Najjar3, 1Rheumatology, Rehabilitation and Physical medicine department - faculty of medicine -Misr University for science and technology, 6th of October, Al Jizah, Egypt, 2Faculty of medicine - Zagazig university, Al Zagazig, Egypt, 3Faculty of medicine - Al-Azhar university in Gaza, Gaza, Palestinian Territories

    Background/Purpose: Carpometacarpal osteoarthritis (CMC OA) is a painful condition affecting 21% of hand OA patients. Various treatment modalities have been explored to reduce pain and…
  • Abstract Number: 1189 • ACR Convergence 2024

    Certain Dosages of Fasinumab Provides Superior Benefits over Placebo in Mitigating Osteoarthritis Symptoms Albeit at Increased Health Detriments: A Systematic Review and Meta-Analysis

    Muhammad Sohaib Khan1, Wania Moeen2, Umm E Salma Shabbar Banatwala2, Muhammad Usman2, Umar Mahmood2, Syed Ashad Ahmed Fatmi2, Syed Muhammad Muneeb Akhtar2, Hania Shahzad3, Muhammad Talal Ibrahim4, Nisar Ahmed5, Badaruddin Sahito2 and Muhammad Sohaib Asghar6, 1Dow University of Health Sciences, Karachi, Pakistan, 2Dow University of Health Sciences, Karachi, Sindh, Pakistan, 3UC Davis Health, Sacramento, CA, 4The Ohio State University Wexner Medical Center, Columbus, OH, 5Rapido’s Clinica Familiar, Chicago, 6AdventHealth, Sebring, FL

    Background/Purpose: Fasinumab, a newly developed anti-nerve growth factor monoclonal antibody, is currently under investigation for its potential to alleviate symptoms in osteoarthritis patients. This meta-analysis…
  • Abstract Number: 1194 • ACR Convergence 2024

    Treatment Effect of Lorecivivint Across Multiple Trials in Patients with Knee OA: A Meta-analysis

    Christopher Swearingen1, Jeyanesh Tambiah2 and Yusuf Yazici3, 1Biosplice Therapeutics, Inc, San Diego, CA, 2Biosplice Therapeutics Inc., San Diego, CA, 3NYU Grossman School of Medicine, La Jolla, CA

    Background/Purpose: Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways has previously appeared safe, improved patient-reported outcomes (PROs) compared with…
  • Abstract Number: 1219 • ACR Convergence 2024

    Association Between Fibromyalgia and Serum Levels of Calcitonin Gene-Related Peptide and Vascular Endothelial Growth Factor: A Meta-Analysis

    Osama Al Zoubi1, Dahlia Chavez2 and Robert Katz3, 1University of Illinois at Chicago, Chicago, IL, 2Rheumatology Associates, Rush University Medical Center, Chicago, IL, 3Rush University Medical Center, Chicago, IL

    Background/Purpose: Fibromyalgia syndrome (FMS) is characterized by generalized muscle pain, fatigue, psychological distress, cognitive dysfunction, and sleep disturbances. The physiopathology of FMS is not fully…
  • Abstract Number: 1384 • ACR Convergence 2024

    Disease-modifying Antirheumatic Drugs and Risk of Incident Interstitial Lung Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Qianru Zhang1, Gregory McDermott2, Sung Hae Chang3, Pierre-Antoine Juge4, Kathleen Vanni5, Grace Qian6, Katarina Bade5, Kevin Mueller5, Emily Kowalski5, Alene Saavedra5 and Jeffrey Sparks7, 1Harard Medical School, Cambridge, 2Brigham and Women's Hospital, Brookline, MA, 3Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, 4Service de Rhumatologie, Hôpital Bichat - Claude-Bernard, AP-HP, Paris, Île-de-France, France, PARIS, Germany, 5Brigham and Women's Hospital, Boston, MA, 6Brigham and Women’s Hospital, Boston, MA, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: Interstitial lung disease (ILD) is a serious extra-articular manifestation of RA, affecting 7-12% of patients and associated with three-fold increased mortality compared to RA…
  • Abstract Number: 1468 • ACR Convergence 2024

    Efficacy of bDMARDs in Early versus Established Disease in Axial Spondyloarthritis: A Meta-Analysis of Randomized Trials

    Diego Benavent1, Victoria Navarro Compán2, Dafne Capelusnik3 and Sofia Ramiro4, 1Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, 2La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 3Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, 4Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: The ASAS consensus definition of ‘early axial spondyloarthritis (axSpA)’ (axial symptoms ≤ 2 years) was expert-based given the scarcity of evidence1. We conducted a…
  • Abstract Number: 1111 • ACR Convergence 2023

    Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis

    Palapun Waitayangkoon1, Tatchaya Kanthajan2 and Thiratest Leesutipornchai3, 1MetroWest Medical Center, Framingham, MA, 2Srinakharinwirot University, Bangkok, Thailand, 3University of Hawaii, Honolulu, HI

    Background/Purpose: Recent studies have suggested that hyperuricemia is significantly associated with an increased prevalence of atrial and ventricular arrhythmias and urate-lowering therapy (ULT) may provide…
  • Abstract Number: 2340 • ACR Convergence 2023

    Multi-targeted Therapy Better in Achieving Complete Response in Lupus Nephritis: A Systematic Review and Meta-analysis

    Omer Pamuk1, Bisma Shaikh2, Saif Khan3, Ali Abbas4, Sarah Abi Doumeth5 and sarfaraz Hasni6, 1University Hospitals Cleveland Medical Center, Cleveland, OH, 2Jinnah Sindh Medical University, Karachi, Pakistan, 3College of Medical and Dental Sciences, Birmingham, United Kingdom, 4Alabama College of Osteopathic Medicine, Dothan, AL, 5Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, 6Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: The overall management of SLE and Lupus Nephritis (LN) has significantly improved over the last four decades.Recently great therapeutic strides have been made in…
  • Abstract Number: 1187 • ACR Convergence 2023

    Post-hoc Analysis of Individual Questions from the Australian/Canadian Osteoarthritis Hand Index from a Randomized, Double-blind, Placebo-controlled Trial of Patients with Hand OA

    Karin Nicholson1, Edwin Sanchez1, Wendy Wright2, Joel Block3 and Richard Petruschke1, 1Haleon, Warren, NJ, 2Wright & Associates Family Healthcare, Amherst, NH, 3Rush University Medical Center, Chicago, IL

    Background/Purpose: Hand osteoarthritis (OA) is a frequently occurring form of OA characterized by symptoms including joint pain, stiffness, and swelling which affect performance of activities…
  • Abstract Number: 2550 • ACR Convergence 2023

    The Incidence of Uveitis in Patients with Axial Spondylarthritis Treated with Biologics or Targeted Synthetics: A Systematic Review and Network Meta-analysis

    Zijing Yang1, Maryam Adas1, Bechman Katie1, Deepak Nagra1, Ali Soykan Uguzlar1, Mark Russell1, Nicky Wilson2, Sophia Steer1, Sam Norton1 and James Galloway1, 1King's College London, London, United Kingdom, 2King's College Hospital, London, United Kingdom

    Background/Purpose: Anterior uveitis (AU) is one of the commonly observed extraspinal manifestations in Axial spondyloarthritis (AxSpA). Data on the protective effects of targeted immunomodulatory therapies…
  • Abstract Number: 1215 • ACR Convergence 2023

    Efficacy of Pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases

    Bayram Farisogullari1, Eduardo Santos2, Emma Dures3, Rinie Geenen4 and Pedro Machado5, 1Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 2Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, 3Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, 4Utrecht University, Vorstenbosch, Netherlands, 5Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom

    Background/Purpose: To identify the best evidence on the efficacy of pharmacological interventions in reducing fatigue in people with I-RMDs and to summarise their safety in…
  • Abstract Number: 1260 • ACR Convergence 2023

    Optimal Approaches for Reducing Depressive Symptoms in Rheumatoid Arthritis Patients Based on Psychological Interventions: A Systematic Review and Network Meta-analysis

    Zhang Lijuan and Wu Beiwen, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Background/Purpose: In recent years, numerous psychological interventions for rheumatoid arthritis (RA) patients have been developed. However, it remains unclear which psychological interventions are effective and…
  • Abstract Number: 1400 • ACR Convergence 2023

    Achieving ASDAS Inactive Disease Status in Axial Spondyloarthritis: A Systematic Review and Meta-analysis

    Sarah Abi Doumeth1, Omer Pamuk2 and Marina Nighat Magrey3, 1Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, 2Division of Rheumatology, Case Western Reserve University/University Hospitals, Cleveland, OH, 3Case Western Reserve University, University Hospitals, Cleveland, OH

    Background/Purpose: ASDAS-CRP is a composite score that measures disease activity in axial spondyloarthritis (axSpA) and is based on patient-reported outcomes and objective measures of inflammation.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology